'Dangerous' dementia drugs to be reviewed
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The prescribing of powerful anti-psychotic drugs to patients with dementia is to be reviewed immediately, ministers have said.
The announcement follows evidence that up to half of GPs are prescribing the drugs as a "chemical cosh" to subdue challenging patients, despite safety warnings issued four years ago. Ivan Lewis, a Health minister, ordered the review at the launch of a proposed national dementia strategy to improve care for the 570,000 sufferers in England.
Two drugs, risperidone and olanzapine, are widely used in treating schizophrenia but carry an increased risk of stroke in elderly patients. However, a recent survey of 355 GPs by BBC Radio 4 found more than half admitted prescribing them.
Mr Lewis said: "This first-ever national dementia strategy... will set out how we will improve the quality of life for people with dementia and their families, improve their quality of care, increase awareness and ensure earlier diagnosis and intervention."
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments